Loading organizations...
§ Private Profile · Cambridge, MA, USA
QurAlis is a technology company.
QurAlis has raised $136.0M across 3 funding rounds.
Key people at QurAlis.
QurAlis has raised $136.0M in total across 3 funding rounds.
QurAlis develops precision therapies for neurodegenerative diseases, focusing on Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD). Their approach deeply understands disease mechanisms, like TDP-43 pathology and the STATHMIN-2 link, identified via human neuronal stem cell models. This enables engineering targeted treatments for specific molecular drivers of these complex conditions.
Founded December 12, 2016, by Harvard neurodegenerative biologists Kasper Roet, Kevin Eggan, and Clifford Woolf, QurAlis arose from a pivotal insight. Scientific discoveries elucidated diverse genetic and molecular pathways in ALS, emphasizing precision medicine. This understanding drives their strategy to treat distinct disease mechanisms with tailored interventions.
QurAlis's pipeline targets patients with devastating neurodegenerative disorders, particularly specific sub-forms of ALS and FTD. The company advances its precision medicines to achieve significant breakthroughs. Its vision is to pioneer a path toward curing these debilitating diseases by precisely targeting their fundamental biological causes.
Key people at QurAlis.
QurAlis has raised $136.0M in total across 3 funding rounds.
QurAlis's investors include Sanofi Ventures, Droia Ventures, Cillian King, 15th Rock Ventures, Amadeus Capital Partners, AMR Action Fund, Oscar Slotboom, Brandon Capital Partners, EQT Life Sciences, Scott Biller, INKEF Capital, Mission BioCapital.
QurAlis has raised $136.0M across 3 funding rounds. Most recently, it raised $88.0M Series B in March 2023.
QurAlis Corporation is a clinical-stage biotechnology company developing precision medicines for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases.[1][5] It builds therapies using proprietary stem cell-derived neuronal models, the FlexASO™ splice modulator platform, and targets like Kv7.2, STATHMIN-2 (STMN2), and UNC13A to address genetic drivers in sporadic ALS and related conditions, serving patients with these devastating diseases where few effective treatments exist.[1][3][7] The company advances a robust pipeline, including three programs—two in clinical stages—with lead candidates like QRL-201 (STMN2) and QRL-101 (Kv7), demonstrating strong growth through milestones like first-in-human dosing, regulatory approvals, and Series B financing.[3][7]
QurAlis was founded on December 12, 2016, in Cambridge, MA, by Drs. Kasper Roet, Kevin Eggan, and Clifford Woolf, alongside Q-State Biosciences—all internationally recognized neurodegenerative biologists from Harvard Medical School and Harvard University.[1][7] Eggan pioneered patient-derived stem cell technology for neuronal models, enabling identification of key ALS genetic targets like Kv7.2 and STATHMIN-2.[1] Early traction included launching three precision medicine programs for ALS subgroups in 2017, winning the Amgen Golden Ticket, selecting QRL-201 as lead candidate in 2021, and achieving pivotal 2023 milestones: first-in-human dosing of QRL-101, Series B raise, new UNC13A program reveal, and clinical trial authorizations (CTAs) from Health Canada, EU, and UK for QRL-201, with first patient dosing.[7]
QurAlis rides the wave of precision medicine in neurodegeneration, cracking sporadic ALS via TDP-43-linked drivers like STMN2 and UNC13A mis-splicing, enabled by stem cell tech and ASO advances.[1][5] Timing aligns with rising genetic insights and regulatory support for orphan diseases, amplified by market forces like urgent ALS unmet needs (few disease-modifying therapies) and biotech investment in RNA-targeted drugs.[2][7] It influences the ecosystem by pioneering sub-type specific treatments, collaborating with thought leaders and advocates, and expanding platforms to neurological disorders, potentially reshaping outcomes for genetically defined patient groups.[3][4]
QurAlis is poised to deliver first-in-class precision therapies, with clinical data from QRL-101 and QRL-201 expected to validate its platforms and drive partnerships or further funding.[7] Trends like ASO maturation, biomarker-driven trials, and global manufacturing will accelerate its pipeline expansion into FTD, epilepsy, and beyond, potentially altering neurodegenerative treatment paradigms.[3][6] As neuro pioneers, QurAlis' relentless focus on patient-derived insights and genetic precision positions it to lead breakthroughs, bringing hope to ALS and FTD communities through trajectory-altering medicines.[1][5]
